U.S. BANK PARTNERS WITH ACCENTIA BIOPHARMACEUTICALS

A A

U.S. Bank has provided the financing to help develop apotentially life-saving therapeutic for non-Hodgkin's lymphoma,marking the first time the New Market Tax Credit (NMTC) program hasbeen used to support a biopharmaceutical company. As part of afinancing arranged with Accentia Biopharmaceuticals, Inc., U.S. Bank purchased $4.6 million of NMTCs as part of aninvestment in a subsidiary of Biovest International, Inc.
Finanzen.net